NCT05175274View on ClinicalTrials.gov

Colchicine Use for Primary Prevention of Coronary Artery Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

6,792

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

March 1, 2027

Study Completion Date

July 1, 2028

Conditions
Coronary Artery Disease
Interventions
DRUG

Colchicine

Colchicine 0.5mg/tablet

DRUG

Placebo

matching placebo

Trial Locations (1)

266042

Mengmei Li, Qingdao

All Listed Sponsors
collaborator

Qingdao Municipal Hospital

OTHER

lead

Qingdao Central Hospital

OTHER

NCT05175274 - Colchicine Use for Primary Prevention of Coronary Artery Disease | Biotech Hunter | Biotech Hunter